Abstract 554P
Background
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a useful diagnostic modality for thoracic lymphadenopathies, including primary lung cancer. However, the specimens obtained are often small and inadequate for pathological diagnosis. We previously reported that using the EchoTip ProCore Endobronchial HD ultrasound needle (EchoTip) increased the tissue diagnosis rate in lung cancer (Miyazaki et al., 2021). In previous studies, the Oncomine Dx Target Test (ODxTT) was performed in only one case, and it is unclear whether the specimens collected could tolerate next-generation sequencing (NGS)-based testing.
Methods
We performed a single-center, retrospective observational study. This study included patients who underwent ODxTT between April 1, 2019 and April 30, 2023. Patients were selected and divided into two groups comprising those who underwent EBUS-TBNA and those whose specimens were obtained by other methods. The ODxTT success rate was calculated for each group. This study was approved by the institutional review board in June 2022. (No. 22-06-05).
Results
We enrolled 144 patients:20 in the EBUS-TBNA group and 124 in the other-methods group. In the EBUS-TBNA group, the pathological diagnoses were adenocarcinoma (Ad), squamous cell carcinoma (Sq), and others in 15, 2, and 3 patients, respectively. In contrast, in the other-methods group, the collection methods were endobronchial biopsy and transbronchial biopsy, surgical procedures, computed tomography-guided needle biopsy, and others for 79, 31, 6, and 8 patients, respectively, and the pathological diagnoses were Ad, Sq, and others in 78, 15, and 31 patients, respectively. The success rates of ODxTT for EBUS-TBNA and others were 90% and 86%, respectively. The DNA and RNA inspection success rates of EBUS-TBNA were 95% and 90%, respectively, and those of the other methods were 90% and 94%, respectively.
Conclusions
The success rate of ODxTT on EBUS-TBNA specimens were 90%. It is expected to yield specimens of sufficient quality and quantity to perform ODxTT and may be an important diagnostic option in lung cancer cases with enlarged lymph nodes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Miyazaki: Financial Interests, Personal, Invited Speaker: AstraZeneca, Merck KGaA, Eli Lilly Japan K.K., Cook Medical Japan; Financial Interests, Institutional, Research Grant: AbbVie GK, MSD, AstraZeneca, Bristol Myers Squibb, Taiho Pharmaceutical CO., LTD. K. Ito, A. Hayashi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK. A. Shiba: Financial Interests, Institutional, Research Grant: AstraZeneca, MSD, Taiho Pharmaceutical CO., LTD., Bristol Myers Squibb, AbbVie GK. Y. Higashi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK. M. Aga: Financial Interests, Personal, Invited Speaker: TEIJIN PHARMA, Nippon Boehringer Ingelheim Co., Ltd.; Financial Interests, Institutional, Research Grant: AbbVie GK, Bristol Myers Squibb, Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca. Y. Hamakawa: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., AstraZeneca, AbbVie GK. Y. Taniguchi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AstraZeneca, AbbVie GK; Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD. Y. Misumi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., Nippon Kayaku CO., LTD., Taiho Pharmaceutical CO., LTD.; Financial Interests, Institutional, Research Grant: MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK, Taiho Pharmaceutical CO., LTD. Y. Agemi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Kyowa Hakko Kirin Co., Ltd.; Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, AbbVie GK, Taiho Pharmaceutical CO., LTD., MSD. Y. Nakamura: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Taiho Pharmaceutical CO., LTD.; Financial Interests, Institutional, Research Grant: AstraZeneca, Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AbbVie GK. T. Shimokawa: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AstraZeneca, AbbVie GK. H. Okamoto: Financial Interests, Institutional, Research Grant: MSD, Taiho, Bristol Myers Squibb.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract